• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies (PAS)

  • Print
  • Share
  • E-mail

The FDA has the authority to require sponsors to perform a post-approval study (or studies) at the time of approval of a premarket approval (PMA), humanitarian device exemption (HDE), or product development protocol (PDP) application. Post-approval studies can provide patients, health care professionals, the device industry, the FDA and other stakeholders information on the continued safety and effectiveness (or continued probable benefit, in the case of an HDE) of approved medical devices. This database allows you to search Post-Approval Study information by applicant or device information.

Learn more...


OSB Lead-Informed Decision Process

Suggest Enhancement / Report Issue | export reports to excelExport to Excel
Study Status Completed
Application Number P020056 / PAS006
Date Current Protocol Accepted 10/17/2006
Study Name OSB Lead-Informed Decision Process
General Study Protocol Parameters
Study Design Cross-Sectional Study
Data Source New Data Collection
Comparison Group No Control
Analysis Type Descriptive
Study Population Adolescent: 13-18 yrs, Transit. Adolescent B (as adults) : 18-21 yrs, Adult: >21
Detailed Study Protocol Parameters
Study Design Description This is a study of the Informed Decision Process Allergan maintains when consenting patients to breast implant surgery. It is intended to survery breast surgeons on the efficiency of their Informed Consent Process and the Use of their Allergan Patient Planner
Study Population Description Each year, a random selection of 50 physicians are targeted for a survey to evaluate the Patient Planner as a collective sourcve of information.
Sample Size 50 physicians annually
Data Collection Survey is administered to 50 physicians and asks questions on the level of understanding a patient has after consulting the Allergan patient planner.
Follow-up Visits and Length of Follow-up There are no follow up visits in this study
Interim or Final Data Summary
Interim Safety Information There is no interim device safety Information from this study
Actual Number of Patients Enrolled The Informed Decision Process consisted of yearly surveys. Each year a different sample was selected for the survey. These are the results for 2011 annual report.

84 surveys were returned. Per the condition of approval, the sponsor did administer the survey to a random selection of 50 physicians.
Actual Number of Sites Enrolled N/A
Patient Follow-up Rate N/A
Final Safety Findings N/A
Final Effect Findings The majority (85.7%) of all respondents are satisfied with the Patient Planner, with 55.9% rating it Very Good and 29.8% rating it Good.
Study Strengths & Weaknesses The sample of physicians was chosen randomly, which is a strength of the study.

However, the observational, cross-sectional design of the study does not allow for any hypothesis testing. The results are descriptional only.

Recommendations for Labeling Changes Allergan is not currently proposing labeling changes based upon the survey results.

OSB Lead-Informed Decision Process Schedule

Report Schedule
Date Due
FDA Receipt
Applicant's Reporting Status
2 year report 11/16/2008 11/13/2008 On Time
3 year report 11/16/2009 10/29/2009 On Time
4 year report 11/16/2010 10/29/2010 On Time
5 year report 11/16/2011 11/03/2011 On Time

Contact Us

Julie Unger
Project Manager, Post-Approval Studies Program
Food and Drug Administration
10903 New Hampshire Ave
WO66-4206v Silver Spring, MD

Phone: (301) 796-6134
Fax: (301) 847-8140

Related Links